The accuracy of magnetic resonance imaging in prostate cancer staging: a single-institution experience.

BACKGROUND: Magnetic resonance imaging (MRI) has a wide reported variation in sensitivity and specificity for staging prostate cancer (PCA). AIMS: We examined the accuracy of MRI in detecting PCA, and in identifying extracapsular extension (ECE) and seminal vesicle invasion (SVI) in PCA patients at our institution. METHODS: We retrospectively reviewed pre-biopsy MRI findings and correlated the same with subsequent radical prostatectomy pathology reports in all patients undergoing radical prostatectomy between 2010 and 2012. Specifically, comparison was made between MRI and pathologic stage. Age, serum prostate-specific antigen level and Gleason score were recorded. RESULTS: MRI detected signal abnormalities in 50 out of 88 PCA patients undergoing radical prostatectomy. Of these, 12 had ECE and 7 had SVI on final histology. The sensitivity and specificity of MRI for detecting ECE were 75 and 100%, respectively. The sensitivity and specificity of MRI for detecting SVI were 16.7 and 100%, respectively. The positive predictive values for determining ECE and SVI were 100% and negative predictive values were 96.2 and 90.6%, respectively. CONCLUSIONS: MRI may be reliable for excluding ECE and SVI in PCA patients where the lesion is visible on MRI. It has a good diagnostic ability for ECE, but is less accurate for identifying SVI. This article supports the use of MRI in the preoperative evaluation of PCA.

Diagnosis of pancreatic carcinoma: role of FDG PET.

OBJECTIVE: The purpose of this study was to investigate the role of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in differentiating benign from malignant disease in patients with possible pancreatic malignancy. SUBJECTS AND METHODS: All patients with a possible diagnosis of pancreatic carcinoma based on CT or ERCP findings were eligible for inclusion in this prospective study. PET imaging of the abdomen was performed in 37 patients and was interpreted as positive if FDG activity in the pancreas exceeded background activity and as negative if activity was less than or equal to background activity. Semiquantitative analysis was performed by calculating a standardized uptake ratio. Studies were reviewed independently by two radiologists, and results were correlated with biopsy results and with CT and ERCP findings. Sensitivity and specificity of FDG PET for revealing pancreatic malignancy was determined. RESULTS: FDG activity in the pancreas was increased in 24 patients, and adenocarcinoma was diagnosed in 22 of these patients (92%). Two patients (8%) with increased activity had benign disease, including one patient with chronic pancreatitis who showed no evidence of tumor at laparotomy and one patient with a mucinous cystic tumor who showed no malignant features at laparotomy. FDG uptake was low or normal in 13 patients, 10 of whom (77%) had benign disease. FDG uptake was also low in three patients with adenocarcinoma, whose tumor size ranged from 2 to 4 cm in diameter. The mean standardized uptake ratio value for malignant disease was 5.1 (range, 1.0-10.1) and for benign disease was 1.9 (range, 0.0-5.8) (p < .001). The sensitivity of FDG PET for revealing malignant disease in the pancreas was 88% and the specificity was 83%. CONCLUSION: FDG PET is a sensitive and specific noninvasive technique for the diagnosis of pancreatic malignancy.

Carcinoid metastases to the liver: role of triple-phase helical CT.

PURPOSE: To evaluate triple-phase helical computed tomography (CT) of carcinoid liver metastases. MATERIALS AND METHODS: Triple-phase helical CT was performed in 31 patients with proved carcinoid liver metastases. Hepatic arterial-dominant phase (HAP) and portal venous-dominant phase (PVP) images were obtained 20 and 70 seconds after intravenous iopamidol injection. Four independent readers reviewed each phase for lesion number, conspicuity, and attenuation relative to liver. Three readers reviewed each phase to determine which phase best showed the lesions. RESULTS: The lesions detected by readers 1-4 were as follows: noncontrast phase, 164, 177, 204, and 229 lesions; HAP, 178, 177, 214, and 238 lesions; and PVP, 180, 189, 215, and 250 lesions (P > .05). On HAP images, readers found that 80, 73, 96, and 102 lesions were hyperattenuating. Consensus indicated there were 206 focal lesions. Of these 206 lesions, 72, 72, and 62 lesions were best seen on the noncontrast phase, HAP, and PVP images, respectively. Six, 28, and six lesions were seen only on the noncontrast phase, HAP, and PVP images, respectively. Two patients had lesions seen only on the HAP images. CONCLUSION: The HAP and, to a lesser extent, the noncontrast phase provide added value in evaluating carcinoid liver metastasis.

Contrast-enhanced CT of intrahepatic and hilar cholangiocarcinoma: delay time for optimal imaging.

OBJECTIVE: The purpose of this study was to determine the optimal time for obtaining delayed images with contrast-enhanced CT in patients who have intrahepatic or hilar cholangiocarcinoma. SUBJECTS AND METHODS: CT studies were performed in 25 consecutive patients with proven cholangiocarcinoma, including six patients who had undergone radiotherapy or chemotherapy. Dynamic images of the liver were obtained after 150 ml of IV contrast material was administered at 3 ml/sec. Delayed CT images were then obtained at 10, 20, and 30 min. Tumor-liver attenuation difference was determined quantitatively for each time period. Images were qualitatively evaluated by three observers for attenuation of the tumor (hypoattenuating, isoattenuating, or hyperattenuating) relative to the liver. Observer confidence for tumor detection was graded on a four-point scale. Dynamic and delayed images were compared for tumor conspicuity. RESULTS: On dynamic images, 18 tumors (72%) were hypoattenuating, six (24%) were isoattenuating, and one was heterogeneous. On delayed images, 15 (60%) of these 25 tumors were isoattenuating and nine (36%) were hyperattenuating compared with the liver. Tumor-liver attenuation difference was greatest on dynamic studies (p < .01) and did not differ significantly among the three delay times (p > .20). All tumors seen on delayed images were also seen on dynamic images; however, in three patients (12%), the confidence level for presence of tumor was better on delayed than on dynamic images. Confidence levels for presence of tumor did not vary significantly among the three delay times. Attenuation values on dynamic and delayed images did not differ for the groups of patients who had or had not undergone prior radiotherapy or chemotherapy (p > .05). CONCLUSION: In the evaluation of hilar or intrahepatic cholangiocarcinoma, delayed CT images are helpful for tumor characterization and may improve observer confidence for the presence of tumor. The optimal time for acquisition of delayed images is 10-20 min after contrast media injection.

Pancreatic malignancy: effect of dual-phase helical CT in tumor detection and vascular opacification.

PURPOSE: To determine the relative value of hepatic arterial and portal venous phase helical computed tomographic (CT) scans for tumor detection and vascular opacification in patients with pancreatic malignancy. MATERIALS AND METHODS: Ninety-five patients who had or were suspected of having pancreatic disease underwent dual-phase helical CT. Arterial phase scans were acquired 20-40 seconds after contrast material administration; venous phase scans, 70-100 seconds after administration. Three readers independently scored images in a blinded fashion for the presence of tumor, for lesion attenuation relative to normal pancreas, and for vascular opacification. RESULTS: The final diagnosis was pancreatic malignancy (n = 60), acute or chronic pancreatitis (n = 22), and normal pancreas (n = 13). The readers identified possible or definite tumors on arterial phase studies in 47-50 patients and on venous phase studies in 48-53 patients (P > .10). There was no statistically significant difference in tumor attenuation between scans from the two phases (P > .05). Agreement between the readers for tumor detection was not affected by the scanning phase (P > .10). Opacification of arteries and of veins was greater on arterial phase scans and on venous phase scans, respectively (P < .001). CONCLUSION: The acquisition of arterial phase scans in addition to venous phase scans does not result in improved detection of pancreatic malignancies.

Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging.

BACKGROUND: Positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) is a useful technique for detection of malignancy. The purpose of this study was to determine if FDG-PET scanning using visual and quantitative analyses can identify patients with recurrent colorectal tumor following abdominoperineal resection. METHODS: Eighteen patients were evaluated for possible local recurrence of rectal carcinoma following abdominoperineal resection. The clinical presentation included rising carcinoembryonic antigen levels (n = 5), increasing size of a presacral mass on computed tomography or magnetic resonance (n = 13), or local symptoms (n = 3). Axial PET images of the pelvis were obtained following an injection of 10 mCi of FDG prior to biopsy. Quantitative analysis was performed by calculation of a standardized uptake ratio (SUR), and the images were interpreted by two radiologists in consensus. FDG-PET findings were correlated with histological or cytological findings and with the clinical outcome. RESULTS: Recurrent malignancy was confirmed in 13 patients by surgery (n = 8) or percutaneous biopsy (n = 5). Benign lesions were confirmed in five patients by surgery (n = 1), biopsy (n = 3), or clinical follow up (n = 1). Visual analysis of the FDG-PET data had a sensitivity of 92.3% (12/13) for recurrent disease (95% confidence limits; 63.9%, 99.8%) and a specificity of 80% (4/5; 95% confidence limits; 28.3%, 99.4%). SUR values were significantly higher in malignant lesions (range = 2.92-19.74, mean = 6.89) than in benign ones (range = 1.40-3.47, mean = 1.96; p = 0.002). CONCLUSION: FDG-PET is an accurate technique for detection of locally recurrent colorectal carcinoma. Visual analysis is equivalent to quantitative analysis for detection of disease.

Percutaneous cholecystostomy: who responds?

OBJECTIVE: Our purpose was to identify clinical or radiologic features predictive of response to percutaneous cholecystostomy performed for the treatment of acute cholecystitis. MATERIALS AND METHODS: The clinical records and radiologic images of patients who underwent percutaneous cholecystostomy for suspected acute cholecystitis between January 1987 and July 1994 were retrospectively reviewed. A response to percutaneous cholecystostomy was defined as an improvement in clinical symptoms and signs or reduction in fever and WBC to normal within 72 hr of percutaneous cholecystostomy. The number and type of radiologic investigations were reviewed by two radiologists. The presence of gallstones, gallbladder wall thickening, distention, and pericholecystic fluid was recorded. The clinical and radiologic findings were analyzed for their relationship to response to percutaneous cholecystostomy. RESULTS: Sixty-one percutaneous cholecystostomies were performed in 37 male and 24 female patients and were technically successful in 59. Thirty-one patients had gallstones, 28 did not. Thirty-one patients were in the intensive care unit, and 15 were ventilated. Complications occurred in six (10%): misplacement of the percutaneous cholecystostomy catheter in the colon (one), exacerbation of sepsis (three), and bile leakage (two). The mortality rate was 2%--one of the patients with septic shock succumbed to a cardiac arrest 3 days after the procedure. Forty-three patients (73%) responded to percutaneous cholecystostomy. Patients with gallstones and symptoms and signs localized to the right upper quadrant of the abdomen were more likely to respond (p = .006). The only individual radiologic feature predictive of a positive response was the presence of pericholecystic fluid in patients with gallstones (p = .03). The presence of all four radiologic findings was also associated with a positive response (p = .039). The results of bile cultures were not predictive of response. Of the 16 nonresponders, six had documented biliary sepsis and cholecystitis. CONCLUSION: Clinical symptoms and signs referable to the gallbladder, the presence of pericholecystic fluid in patients with gallstones, and the presence of an increasing number of radiologic findings in any one patient are predictive of a positive response to percutaneous cholecystostomy.

Zebra pattern: a diagnostically challenging hepatic parenchymal enhancement pattern at CT arterial portography.

PURPOSE: To investigate the effect of arterial injection site and splenic volume on the hepatic zebra pattern seen at computed tomographic (CT) arterial portography. MATERIALS AND METHODS: Images from CT arterial portographic examinations, performed via either the splenic artery (SA)(n = 47) or superior mesenteric artery (SMA)(n = 51) in 98 patients, were reviewed. The hepatic parenchymal enhancement pattern was assessed by three blinded reviewers. Splenic volume was determined. RESULTS: Twenty-two of 98 (22%) CT arterial portographic studies showed a zebra pattern: 10 of 47 (21%) with injection via the SA and 12 of 51 (24%) with injection via the SMA. The mean percentage of hepatic parenchyma with nontumorous perfusion defects was 55% with the zebra pattern versus 12% without (P < .001). For SA injections, the mean splenic volume was lower in patients with the zebra patterns (321 vs 409 cm3, P = .09). For SMA injections, it was higher in patients with zebra patterns (372 vs 291 cm3, P = .10). CONCLUSION: The zebra pattern can cause difficulties in interpreting images. It is due to alternating, well-defined regions of portal venous hyper- and hypoperfusion; it likely has a multifactorial cause and is likely due to technical parameters such as the injection site, the volume of the spleen, and the hemodynamic effects of the tumor.

CT during arterial portography: comparison of injection into the splenic versus superior mesenteric artery.

PURPOSE: To determine whether the diagnostic quality of computed tomography (CT) during arterial portography (CTAP) performed via the splenic artery (SA) is better than that performed via the superior mesenteric artery (SMA). MATERIALS AND METHODS: The authors evaluated CTAP images obtained in 98 patients from 1991 to 1994; 47 examinations were performed via the SA and 51 were performed via the SMA. Images were reviewed, by consensus, by three radiologists blinded to catheter location. Hepatic enhancement was quantitatively assessed in 53 patients (31 in the SA group, 22 in the SMA group). RESULTS: The numbers of low-attenuation non-tumor-related perfusion defects (19 in the SA group, 17 in the SMA group), high-attenuation non-tumor-related perfusion defects (six in the SA group, six in the SMA group), diffuse mottled perfusion abnormalities (six in the SA group, five in the SMA group), and portal venous flow defects (20 in the SA group, 20 in the SMA group) were similar in both groups (P > .05). Peak hepatic enhancement was similar in both groups (SMA group = 111 HU; SA group = 112 HU) (P > .05). CONCLUSION: There is no difference in quality between CTAP performed via the SA versus CTAP performed via the SMA.

The hepatopulmonary syndrome: radiologic findings in 10 patients.

OBJECTIVE: The purpose of this study was to review the radiologic manifestations of the hepatopulmonary syndrome. MATERIALS AND METHODS: We retrospectively reviewed clinical records, chest radiographs, 99m Tc-macroaggregated albumin (MAA) perfusion lung scans, chest CT scans, and pulmonary angiograms of 10 patients with proven hepatopulmonary syndrome. RESULTS: Chest radiographs showed basilar, medium-sized (1.5-3.0 mm) nodular or reticulonodular opacities in all cases. CT was done in eight cases and showed basilar dilatation of lung vessels with a larger than normal number of visible branches. The vascular basis for these opacities was best appreciated on conventional CT scans of 10-mm sections. No individual arteriovenous malformations were seen on CT scans. High-resolution CT scans showed no evidence of interstitial fibrosis. 99mTc-MAA perfusion lung imaging, done in seven patients, showed pulmonary arteriovenous shunting in five. Contrast echocardiography confirmed intrapulmonary shunting in these five patients. Pulmonary angiography, done in four cases, showed subtle distal vascular dilatation in two and moderate dilatation with early venous filling in two but did not reveal any individual arteriovenous malformations. CONCLUSION: Chest radiographs in hepatopulmonary syndrome usually show bibasilar nodular or reticulonodular opacities. Conventional CT shows that these opacities represent dilated lung vessels. High-resolution CT is useful in excluding pulmonary fibrosis or emphysema as the cause of these opacities. 99mTc-MMA perfusion imaging or contrast echocardiography can be used to confirm intrapulmonary arteriovenous shunting.

Malignant melanoma metastatic to the gastrointestinal tract.

Malignant melanoma, a common malignancy whose prevalence is increasing, represents 1-3% of cancers in the United States [1]. At autopsy, metastatic deposits to the gut are frequently found, but less than 9% of melanoma patients are diagnosed with gastrointestinal metastases while living [2]. Modern management includes aggressive surgical therapy to prolong survival and to palliate the disease [3]. Therefore, imaging of metastatic melanoma is clinically important to detect extent and determine whether the patient would benefit by surgery. Gastrointestinal metastases may manifest as mucosal or submucosal masses, serosal implants, or carcinomatosis [4]. They arise more commonly in the mesentery or distal small bowel than the proximal gastrointestinal tract or colon. The purpose of this essay is to illustrate the appearance of melanoma metastatic to the gastrointestinal tract on luminal contrast studies and on CT and to emphasize the importance of early investigation of gastrointestinal symptoms in a patient with a history of malignant melanoma.

Preoperative MR imaging in hyperparathyroidism: results and factors affecting parathyroid detection.

OBJECTIVE: To determine the sensitivity of MR imaging for the detection of abnormal parathyroid glands in patients with biochemical evidence of hyperparathyroidism and to identify the factors affecting detection. SUBJECTS AND METHODS: Between 1985, 82 patients with biochemical proof of hyperparathyroidism were referred for MR imaging of the parathyroid glands prior to surgery. Axial T1- (600/20 [TR/TE]) and T2-weighted (2500/40, 80) spin-echo images were obtained using an anterior neck surface coil. The interpretation of the MR image was compared with the findings at surgery and also correlated with gland histology, volume, and weight. Cases in which a false-positive or false-negative diagnosis was made were reviewed to determine the factors affecting detection. RESULTS: MR imaging detected 71 of 92 (77%) surgically proven abnormal glands (sensitivity, 77%; 95% confidence interval (CI), 68-86%) and misdiagnosed five (1.6%) of 314 normal glands as abnormal. There was no difference in the detection of enlarged glands in patients presenting for the first time (n = 71) (sensitivity, 77%; 95% CI, 66-86%) compared with patients with recurrent hyperparathyroidism (n = 12) (sensitivity, 77%; 95% CI, 46-95%). There was no significant difference in the detection of adenomas (sensitivity, 77%; 95% CI, 65-86%) compared with hyperplasia (sensitivity, 71%; 95% CI, 42-92%). Of five patients with ectopic parathyroid glands (1.6%), four had had previous surgery. All five glands were successfully located (three mediastinal, two in the neck). Factors contributing to a false-negative MR imaging diagnosis included small gland size and thyroid disease. Four of five false-positive diagnoses were due to enlarged lymph nodes being mistaken for parathyroid glands. CONCLUSIONS: MR imaging is an accurate technique for investigation of hyperparathyroidism. Pitfalls include low sensitivity for the identification of small glands, misinterpretation of enlarged lymph nodes as parathyroid adenomas, and misinterpretation because of thyroid disease. MR imaging is particularly useful in the investigation of patients who remain hypercalcemic following initial surgery.

Percutaneous transhepatic liver biopsy with tract embolization.

PURPOSE: To determine the success and safety of percutaneous transhepatic liver biopsy with tract embolization (PBTE) in patients at risk for standard transhepatic biopsy. MATERIALS AND METHODS: Eighty biopsies were performed in 76 patients with diffuse liver disease: 57 biopsies in patients with coagulopathy (11 of whom also had ascites), 16 in patients with mild coagulopathy and ascites, and seven in patients with ascites only. Biopsy was performed with a cutting needle placed through a 10-cm vascular sheath. Gelatin sponge was the embolization agent. RESULTS: All 80 biopsy specimens (100%) were adequate for histopathologic diagnosis. Six complications (8%) resulted from the procedure: one bleeding complication due to incomplete tract embolization, two bowel injuries, one hemobilia, one intercostal artery injury, and one posterior liver capsule perforation with bleeding. All complications occurred in patients with coagulopathy and with the operator's first or second PBTE. CONCLUSION: PBTE produces excellent diagnostic specimens. The high complication rate empirically appears to be related to the degree of coagulopathy and operator experience.

Prospective evaluation of pulmonary artery pressures during pulmonary angiography performed with low-osmolar nonionic contrast media.

PURPOSE: To determine the effects of pulmonary angiography performed with low-osmolar, nonionic contrast media on pulmonary artery pressures. PATIENTS AND METHODS: In a prospective, uncontrolled clinical trial, pulmonary artery pressures (systolic, diastolic, mean) of 116 patients referred for pulmonary angiography were recorded before and 1 and 5 minutes after injection of contrast material. RESULTS: There was a statistically significant rise in systolic, diastolic, and mean pulmonary artery pressure at 1 minute (4.6, 3.4, 4.1 mm Hg, respectively) and 5 minutes (3.8, 2.7, 3.4 mm Hg, respectively) after the initial contrast material injection (P < .05). Increases were smaller with additional injections. Systolic pressure changes at 1 and 5 minutes after the first injection were linearly dependent on the volume of contrast material injected (P < .05). There was no statistically significant difference in the increase in pulmonary artery pressure between patients with pulmonary embolus or pulmonary arterial hypertension and those without. CONCLUSION: There is a small but statistically significant rise in pulmonary artery pressure after injection of low-osmolar, nonionic contrast material for pulmonary angiography; it is unlikely to be of clinical significance.

Pulmonary angiography performed with iopamidol: complications in 1,434 patients.

PURPOSE: To evaluate the safety of pulmonary angiography performed with iopamidol compared with pulmonary angiography performed with ionic contrast media. MATERIALS AND METHODS: The data in 1,434 patients who underwent pulmonary angiography with iopamidol 76% were retrospectively reviewed. Complications that occurred within 48 hours were identified with review of hospital charts and/or computer records. RESULTS: Pulmonary arterial hypertension was present in 402 patients and was severe in 99. Pulmonary embolus was diagnosed in 357 patients (24.9%). Major complications occurred in four patients (0.3%). Respiratory insufficiency occurred in two of these patients. Catheterization was not completed in two patients due to catheter-induced cardiac arrhythmia that was refractory to treatment. No procedure-related deaths occurred. During the periprocedural period, eight patients required intubation and 10 patients died; all patients previously were critically ill. CONCLUSION: Pulmonary angiography is a safe procedure, and the margin of safety is enhanced by the use of iopamidol.